Kevin W McDonald

Title: Kevin W McDonald: Innovator in HIV Research

Introduction

Kevin W McDonald is a notable inventor based in Merrimack, NH (US). He has made significant contributions to the field of medical research, particularly in the area of HIV treatment. With a total of four patents to his name, McDonald has focused on developing compounds that can inhibit HIV infectivity.

Latest Patents

One of McDonald's latest patents involves a compound for inhibiting HIV infectivity. This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids, such as formaldehyde naphthalenesulfonic acid condensation polymers, can effectively abrogate HIV gp120 binding to CD4. This has been demonstrated through CD4/gp120 binding assays. In addition to inhibiting gp120 binding, these compounds have shown the ability to inhibit HIV-induced syncytia formation and the infectivity of CD+ cells. Importantly, the use of this compound has been found to be non-cytotoxic and does not inhibit antigen-induced T lymphocyte proliferation. Based on these findings, these compounds can serve as therapeutic agents for the treatment of acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), AIDS-related dementia, and non-symptomatic HIV infection. Furthermore, the compounds can also be utilized to treat blood preparations.

Career Highlights

Kevin W McDonald is currently associated with Procept Corporation, where he continues to innovate in the field of HIV research. His work has been instrumental in advancing therapeutic options for individuals affected by HIV.

Collaborations

Some of McDonald's notable coworkers include Shyam K Singh and Raymond J Patch, who have collaborated with him on various projects within the company.

Conclusion

Kevin W McDonald is a dedicated inventor whose work in HIV research has the potential to make a significant impact on public health. His innovative compounds represent a promising avenue for the treatment of HIV and related conditions.